2026 Core General Surgery Updates-Part 7
The Critical Edge
16 views
This collection of academic and regulatory documents focuses on medical guidelines for specialized patient care and drug administration. A portion of the material offers a systematic review regarding the perioperative management of oral blood thinners, while official FDA labeling provides specific usage instructions for the anticoagulant apixaban. Additionally, the sources include a comprehensive evaluation of gene expression assays used to determine the most effective postoperative therapies for early-stage breast cancer. Collectively, these texts serve as a resource for healthcare professionals navigating complex treatment protocols and surgical safety. By bridging the gap between pharmacological data and clinical decision-making, the sources aim to optimize patient outcomes in both oncology and cardiology.
DISCLAIMER
The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns.
Perioperative Anticoagulation and Genomic Oncology: A Comprehensive Study Guide
TOP TEN TAKEAWAYS
1. Systematic Review of DOACs: A significant systemic review was conducted by Sunkara et al. focusing on the perioperative management of direct oral anticoagulants (DOACs), providing a clinical framework for surgical patient care.
2. Definition of DOACs: The acronym DOAC refers to Direct Oral Anticoagulants, a class of medication requiring specific management protocols during the perioperative period.
3. FDA Regulatory Oversight: The Food and Drug Administration (FDA) released the official drug label for ELIQUIS (apixaban) in December 2012, establishing its initial regulatory and safety guidelines.
4. Clinical Utility of Apixaban: ELIQUIS, known generically as apixaban, is a primary entity in the study of anticoagulant labeling and safety data.
5. Adjuvant Systemic Therapy Selection: Current research in surgical oncology emphasizes the selection of postoperative adjuvant systemic therapy for patients diagnosed with early-stage breast cancer.
6. Gene Expression Assays: Commercially available gene expression assays are critical tools used by clinicians to assess and determine the most appropriate therapy for breast cancer patients.
7. Updated Oncology Assessments: As of 2024, updated assessments and systematic reviews (Hyams et al.) have been published to evaluate the efficacy of leading genomic assays in the context of breast cancer.
8. Publication Venues for Anticoagulation: Research regarding the management of DOACs can be found in specialized journals such as Health Services Insights.
9. Surgical Oncology Literature: The Journal of Surgical Oncology serves as a primary source for peer-reviewed evaluations of cancer treatment assays and systemic therapy selections.
10. Temporal Scope of Evidence: The provided literature spans from 2012 (FDA labeling) to 2024 (updated oncology reviews), reflecting over a decade of evolving clinical data in anticoagulation and oncology.
STUDY GUIDE
The provided source context focuses on two primary medical domains: the perioperative management of anticoagulation and the genomic-driven selection of therapy in surgical oncology. This study guide organizes these topics by their research scope and regulatory foundations.
I. Perioperative Management of Direct Oral Anticoagulants (DOACs)
The management of patients on Direct Oral Anticoagulants (DOACs) during the period surrounding a surgical procedure—the perioperative period—is a critical area of clinical focus. A systemic review by Sunkara et al., published in Health Services Insights (2016), addresses the complexities of these medications.
• Objective of the Review: To synthesize existing data on the perioperative handling of DOACs to ensure patient safety and minimize bleeding or thrombotic risks.
• Key Researchers: The review was authored by a team including Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, and Reddy M.
• Contextual Importance: As DOACs have become more prevalent, the need for standardized perioperative protocols, as outlined in this systemic review, has become essential for surgical teams.
II. FDA Regulatory Framework for Apixaban (ELIQUIS)
Official regulatory documentation provides the ground truth for the clinical use of specific anticoagulants. The Food and Drug Administration (FDA) label for ELIQUIS (apixaban) is a cornerstone document for this medication.
• Chronology: The label was published in December 2012, marking a significant p...
2026 Core General Surgery Updates-Part 7
The Critical Edge
16 views
This collection of academic and regulatory documents focuses on medical guidelines for specialized patient care and drug administration. A portion of the material offers a systematic review regarding the perioperative management of oral blood thinners, while official FDA labeling provides specific usage instructions for the anticoagulant apixaban. Additionally, the sources include a comprehensive evaluation of gene expression assays used to determine the most effective postoperative therapies for early-stage breast cancer. Collectively, these texts serve as a resource for healthcare professionals navigating complex treatment protocols and surgical safety. By bridging the gap between pharmacological data and clinical decision-making, the sources aim to optimize patient outcomes in both oncology and cardiology.
DISCLAIMER
The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns.
Perioperative Anticoagulation and Genomic Oncology: A Comprehensive Study Guide
TOP TEN TAKEAWAYS
1. Systematic Review of DOACs: A significant systemic review was conducted by Sunkara et al. focusing on the perioperative management of direct oral anticoagulants (DOACs), providing a clinical framework for surgical patient care.
2. Definition of DOACs: The acronym DOAC refers to Direct Oral Anticoagulants, a class of medication requiring specific management protocols during the perioperative period.
3. FDA Regulatory Oversight: The Food and Drug Administration (FDA) released the official drug label for ELIQUIS (apixaban) in December 2012, establishing its initial regulatory and safety guidelines.
4. Clinical Utility of Apixaban: ELIQUIS, known generically as apixaban, is a primary entity in the study of anticoagulant labeling and safety data.
5. Adjuvant Systemic Therapy Selection: Current research in surgical oncology emphasizes the selection of postoperative adjuvant systemic therapy for patients diagnosed with early-stage breast cancer.
6. Gene Expression Assays: Commercially available gene expression assays are critical tools used by clinicians to assess and determine the most appropriate therapy for breast cancer patients.
7. Updated Oncology Assessments: As of 2024, updated assessments and systematic reviews (Hyams et al.) have been published to evaluate the efficacy of leading genomic assays in the context of breast cancer.
8. Publication Venues for Anticoagulation: Research regarding the management of DOACs can be found in specialized journals such as Health Services Insights.
9. Surgical Oncology Literature: The Journal of Surgical Oncology serves as a primary source for peer-reviewed evaluations of cancer treatment assays and systemic therapy selections.
10. Temporal Scope of Evidence: The provided literature spans from 2012 (FDA labeling) to 2024 (updated oncology reviews), reflecting over a decade of evolving clinical data in anticoagulation and oncology.
STUDY GUIDE
The provided source context focuses on two primary medical domains: the perioperative management of anticoagulation and the genomic-driven selection of therapy in surgical oncology. This study guide organizes these topics by their research scope and regulatory foundations.
I. Perioperative Management of Direct Oral Anticoagulants (DOACs)
The management of patients on Direct Oral Anticoagulants (DOACs) during the period surrounding a surgical procedure—the perioperative period—is a critical area of clinical focus. A systemic review by Sunkara et al., published in Health Services Insights (2016), addresses the complexities of these medications.
• Objective of the Review: To synthesize existing data on the perioperative handling of DOACs to ensure patient safety and minimize bleeding or thrombotic risks.
• Key Researchers: The review was authored by a team including Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, and Reddy M.
• Contextual Importance: As DOACs have become more prevalent, the need for standardized perioperative protocols, as outlined in this systemic review, has become essential for surgical teams.
II. FDA Regulatory Framework for Apixaban (ELIQUIS)
Official regulatory documentation provides the ground truth for the clinical use of specific anticoagulants. The Food and Drug Administration (FDA) label for ELIQUIS (apixaban) is a cornerstone document for this medication.
• Chronology: The label was published in December 2012, marking a significant p...